Trevena
Update in progressTRVN (OTC Markets OTCPK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Trevena, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. Its lead programs include OLINVYK (Oliceridine) injection, a G protein–biased mu-opioid receptor ligand for moderate-to-severe acute pain; TRV734, a MOR-biased small molecule that has completed Phase I trials for acute and chronic pain; and TRV045, a novel S1P modulator for chronic pain. Founded in 2007, based in Chesterbrook, Pennsylvania.
Company score
- Sentiment
- 0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCPK (PNK)
- LocationUnited States
- CEOMs. Carrie L. Bourdow
- Founded2007
- Employees23
- Websitewww.trevena.com
Identifiers
- ISINUS89532E1091
- FIGIBBG001J1BLF9
- LEI549300YXUV4MU2J7QS07
- CUSIP89532E109
- CIK0001429560